Top

Published in:

01-12-2014 | ASTHMA (WJ CALHOUN AND SP PETERS, SECTION EDITORS)

Emerging Issues in Pediatric Asthma: Gaps in EPR-3 Guidelines for Infants and Children

Author: Daniel J. Jackson

Published in: Current Allergy and Asthma Reports | Issue 12/2014

Abstract

There are many complexities to the treatment of infants and children with recurrent wheezing and asthma. The National Heart, Lung and Blood Institute’s (NHLBI’s) Expert Panel Report-3 (EPR-3), published in 2007, provides guidance to clinicians who care for infants and children with asthma. Since that time, many important clinical trials have further informed the evidence base available to clinicians. In this manuscript, new approaches to long-term therapy, intermittent fixed-dose and dynamic dose therapies, and emerging therapies for asthma are reviewed. Further, additional gaps in guideline-based care and areas for future research are discussed.

Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. 2007 www.nhlbi.nih.gov/guidelines/asthma/.

Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008;178:667–72.PubMedCentralPubMedCrossRef

Bisgaard H, Hermansen MN, Bonnelykke K, Stokholm J, Baty F, Skytt NL, et al. Association of bacteria and viruses with wheezy episodes in young children: prospective birth cohort study. BMJ. 2010;341:c4978.PubMedCentralPubMedCrossRef

Akinbami LJ, Moorman JE, Bailey C, Zahran HS, King M, Johnson CA, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010. NCHS Data Brief. 2012;2012:1–8.

Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. N Engl J Med. 1995;332:133–8.PubMedCrossRef

Savenije OE, Granell R, Caudri D, Koppelman GH, Smit HA, Wijga A, et al. Comparison of childhood wheezing phenotypes in 2 birth cohorts: ALSPAC and PIAMA. J Allergy Clin Immunol. 2011;127:1505–1512 e1-14.PubMedCrossRef

Brand PL, Baraldi E, Bisgaard H, Boner AL, Castro-Rodriguez JA, Custovic A, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J. 2008;32:1096–110.PubMedCrossRef

Krawiec ME, Westcott JY, Chu HW, Balzar S, Trudeau JB, Schwartz LB, et al. Persistent wheezing in very young children is associated with lower respiratory inflammation. Am J Respir Crit Care Med. 2001;163:1338–43.PubMedCrossRef

Saglani S, Malmstrom K, Pelkonen AS, Malmberg LP, Lindahl H, Kajosaari M, et al. Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction. Am J Respir Crit Care Med. 2005;171:722–7.PubMedCrossRef

10.

Saglani S, Payne DN, Zhu J, Wang Z, Nicholson AG, Bush A, et al. Early detection of airway wall remodeling and eosinophilic inflammation in preschool wheezers. Am J Respir Crit Care Med. 2007;176:858–64.PubMedCrossRef

11.

Payne DN, Qiu Y, Zhu J, Peachey L, Scallan M, Bush A, et al. Airway inflammation in children with difficult asthma: relationships with airflow limitation and persistent symptoms. Thorax. 2004;59:862–9.PubMedCentralPubMedCrossRef

12.

Strunk RC, Sternberg AL, Szefler SJ, Zeiger RS, Bender B, Tonascia J. Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents. J Pediatr. 2009;154:682–7.PubMedCentralPubMedCrossRef

13.

Bisgaard H, Allen D, Milanowski J, Kalev I, Willits L, Davies P. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics. 2004;113:e87–94.PubMedCrossRef

14.

Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354:1985–97.PubMedCrossRef

15.

Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, Le Souef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108:E48.PubMedCrossRef

16.

Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med. 2005;171:315–22.PubMedCrossRef

17.

Szefler SJ, Baker JW, Uryniak T, Goldman M, Silkoff PE. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol. 2007;120:1043–50.PubMedCrossRef

18.

Lemanske Jr RF, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010;362:975–85.PubMedCentralPubMedCrossRef

19.

Vaessen-Verberne AA, van den Berg NJ, van Nierop JC, Brackel HJ, Gerrits GP, Hop WC, et al. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. Am J Respir Crit Care Med. 2010;182:1221–7.PubMedCrossRef

20.

Gappa M, Zachgo W, von Berg A, Kamin W, Stern-Strater C, Steinkamp G. Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED). PediatrPulmonol. 2009;44:1132–42.

21.

Chowdhury BA, Dal PG. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med. 2010;362:1169–71.PubMedCrossRef

22.

Krishnan JA, Bender BG, Wamboldt FS, Szefler SJ, Adkinson Jr NF, Zeiger RS, et al. Adherence Ancillary Study G. Adherence to inhaled corticosteroids: an ancillary study of the Childhood Asthma Management Program clinical trial. J Allergy Clin Immunol. 2012;129:112–8.PubMedCentralPubMedCrossRef

23.

Guilbert TW, Mauger DT, Allen DB, Zeiger RS, Lemanske RF, Jr., Szefler SJ, Strunk RC, Bacharier LB, Covar R, Sorkness CA, Taussig LM, Martinez FD. Growth of preschool children at high risk for asthma 2 years after discontinuation of fluticasone. J Allergy Clin Immunol. 2011;128: 956-963 e951-957.

24.•

Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS, Raissy HH, Van Natta ML, Tonascia J, Strunk RC. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med, 2012. Follow-up of the CAMP study demonstrates persistent small effects of ICS on adult height

25.

Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med. 2005;352:1519–28.PubMedCrossRef

26.

Bacharier LB, Phillips BR, Zeiger RS, Szefler SJ, Martinez FD, Lemanske Jr RF, et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol. 2008;122:1127–35.PubMedCentralPubMedCrossRef

27.••

Zeiger RS, Mauger D, Bacharier LB, Guilbert TW, Martinez FD, Lemanske Jr RF, et al. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med. 2011;365:1990–2001. Important clinical trial demonstrating that intermittent high-dose ICS is an alternative therapy to daily ICS in preschool children with severe intermittent wheezing.PubMedCentralPubMedCrossRef

28.

Ducharme FM, Lemire C, Noya FJD, Davis GM, Alos N, Leblond H, et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med. 2009;360:339–53.PubMedCrossRef

29.

Oborne J, Mortimer K, Hubbard RB, Tattersfield AE, Harrison TW. Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Am J Respir Crit Care Med. 2009;180:598–602.PubMedCrossRef

30.

O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171:129–36.PubMedCrossRef

31.

Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007;356:2040–52.PubMedCrossRef

32.•

Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske Jr RF, Mauger DT, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:650–7. Clinical trial identifying dynamic dosing with rescue ICS in combination with albuterol provides an efficacious option for stepping down from daily ICS in children with mild persistent asthma.PubMedCrossRef

33.

Bisgaard H, Le RP, Bjamer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest. 2006;130:1733–43.PubMedCrossRef

34.

Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleecker ER, Castro M, et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA. 2012;308:987–97.PubMedCentralPubMedCrossRef

35.

O’Byrne PM. Acute asthma intervention: insights from the STAY study. J Allergy Clin Immunol. 2007;119:1332–6.PubMedCrossRef

36.

Rank MA, Hagan JB, Park MA, Podjasek JC, Samant SA, Volcheck GW, et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;131:724–9.PubMedCrossRef

37.

Hagan JB, Samant SA, Volcheck GW, Li JT, Hagan CR, Erwin PJ, et al. The risk of asthma exacerbation after reducing inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. Allergy. 2014;69:510–6.PubMedCrossRef

38.

Bateman ED, Jacques L, Goldfrad C, Atienza T, Mihaescu T, Duggan M. Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. J Allergy Clin Immunol. 2006;117:563–70.PubMedCrossRef

39.

Koenig SM, Ostrom N, Pearlman D, Waitkus-Edwards K, Yancey S, Prillaman BA, et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are “stepped-down”. J Asthma. 2008;45:681–7.PubMedCrossRef

40.

Reddel HK, Gibson PG, Peters MJ, Wark PA, Sand IB, Hoyos CM, et al. Down-titration from high-dose combination therapy in asthma: removal of long-acting beta(2)-agonist. Respir Med. 2010;104:1110–20.PubMedCrossRef

41.

Oommen A, Lambert PC, Grigg J. Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial. Lancet. 2003;362:1433–8.PubMedCrossRef

42.

Panickar J, Lakhanpaul M, Lambert PC, Kenia P, Stephenson T, Smyth A, et al. Oral prednisolone for preschool children with acute virus-induced wheezing. N Engl J Med. 2009;360:329–38.PubMedCrossRef

43.•

Beigelman A, King TS, Mauger D, Zeiger RS, Strunk RC, Kelly HW, et al. Do oral corticosteroids reduce the severity of acute lower respiratory tract illnesses in preschool children with recurrent wheezing? J Allergy Clin Immunol. 2013;131:1518–25. This post hoc analysis provides further evidence to question the efficacy of oral corticosteroids in preschool children with recurrent wheezing.PubMedCrossRef

44.

Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210-16.

45.••

Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364:1005–15. Clinical trial in inner-city children demonstrating the efficacy of omalizumab for the treatment of children down to the age of 6 years, most notably preventing severe exacerbations.PubMedCentralPubMedCrossRef

46.

Busse W, Buhl R, Fernandez Vidaurre C, Blogg M, Zhu J, Eisner MD, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol. 2012;129:983–989 e986.PubMedCrossRef

47.

Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ, Holgate S. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol: Pract 2014.

48.

Jackson DJ, Hartert TV, Martinez FD, Weiss ST, Fahy JV. Asthma: NHLBI Workshop on the primary prevention of chronic lung diseases. Ann Am Thorac Soc. 2014;11 Suppl 3:S139–45.PubMedCrossRef

49.

Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973–84.PubMedCentralPubMedCrossRef

50.

Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985–93.PubMedCrossRef

51.

Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–9.PubMedCrossRef

52.

Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088–98.PubMedCrossRef

53.

Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455–66.PubMedCrossRef

54.

Djukanovic R, Harrison T, Johnston SL, Gabbay F, Wark P, Thomson NC, Niven R, Singh D, Reddel HK, Davies DE, Marsden R, Boxall C, Dudley S, Plagnol V, Holgate ST, Monk P. The effect of inhaled interferon-beta on worsening of asthma symptoms caused by viral infections: a randomised trial. Am J Respir Crit Care Med. 2014.

55.

Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363:1715–26.PubMedCentralPubMedCrossRef

56.

Kerstjens HA, Disse B, Schroder-Babo W, Bantje TA, Gahlemann M, Sigmund R, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol. 2011;128:308–14.PubMedCrossRef

57.•

Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367:1198–207. Two clinical trials demonstrate the efficacy of tiotropium as add-on therapy in adult patients treated with ICS/LABA combination.PubMedCrossRef

58.

Cook AL, Kinane TB, Nelson BA. Tiotropium use in pediatric patients with asthma or chronic cough: a case series. Clin Pediatr (Phila). 2014.

Title: Emerging Issues in Pediatric Asthma: Gaps in EPR-3 Guidelines for Infants and Children
Author: Daniel J. Jackson
Publication date: 01-12-2014
Publisher: Springer US
Published in: Current Allergy and Asthma Reports / Issue 12/2014
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-014-0477-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Emerging Issues in Pediatric Asthma: Gaps in EPR-3 Guidelines for Infants and Children

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2014

Anticholinergics/Antimuscarinic Drugs in Asthma

Immunotherapy for House Dust Mite Sensitivity: Where Are the Knowledge Gaps?

Modified Allergens and their Potential to Treat Allergic Disease

The Expanding Spectrum of Human coronin 1A deficiency

The Nasal and Sinus Microbiome in Health and Disease

Complementary and Alternative Therapy (CAM) in the Treatment of Allergic Rhinitis